Clinical Groups Call For 'Me-Too' Pathway For Infectious Disease LDT Approvals
This article was originally published in The Gray Sheet
A group of infectious disease and clinical virology societies are asking FDA to establish an alternative under the agency's proposed lab-developed test framework for infectious disease test services. Clinical laboratories should be able to use commercial high-risk tests as predicates for ID LDTs so they won't have to go through the costly PMA submissions process.
Register for our free email digests: